The FDA’s approval of TPOXX® (tecovirimat) — the first and only approved antiviral treatment for smallpox — marks a milestone for biosecurity and a triumph against one of the most deadly diseases in history. The approval also serves as an exemplary model of government working collaboratively with its interagency partners and industry to meet a national biodefense need.

At-Home Influenza
Tests Take Leap Forward

HHS, DoD, Spero Co-Sponsor Oral
Antibiotic to Treat Deadly Infections

2,000+ Emergency Response
Professionals Gather in Atlanta for
NDMS Training Summit

Just Released:
Blood and Blood Products Topic
Collection

Mark Your Calendars for
BARDA Industry Day 2018

Just Added: EMS Considerations
for No-Notice Incidents